908 Devices (MASS) Canaccord Genuity's 46th Annual Growth Conference summary

Strategic focus and market transition

• Shifted from bioprocessing/biopharma to handheld chemical detection for public safety and defense, divesting non-core business lines 15 months ago.

• Emphasizes rapid, field-based chemical analysis to address law enforcement and hazmat needs, reducing forensic lab backlogs and enabling faster case resolution.

• Growth driven by addressing synthetic opioid crises and toxic industrial chemical threats globally.

• Leveraging cloud connectivity for real-time data, trend analysis, and improved resource allocation.

• International expansion supported by recent acquisitions and a strong sales channel, especially in Europe.

Product portfolio and innovation

• Flagship MX908 device is highly sensitive, used for synthetic opioids, chemical weapons, and non-traditional agents; over 3,000 units deployed.

• VipIR integrates FTIR and Raman technologies for bulk chemical identification, targeting customs, ports, and hazmat teams.

• NIRLab, acquired recently, offers rapid, cloud-connected drug screening at a lower price point, expanding reach to routine police operations.

• Product pricing ranges from $10,000 (NIRLab) to over $100,000 (VipIR), with deployment scaling from individual officers to large military units.

• Next-generation MX908 in development, aiming for reduced size, weight, and enhanced connectivity.

Regulatory and funding environment

• Legislative changes in several states are driving demand for digital drug screening devices over traditional colorimetric kits.

• Chain of custody and evidentiary integrity are enhanced by cloud-connected devices, supporting regulatory compliance.

• Significant federal and state grant funding (e.g., HIDTA, COPS, UASI) is available for equipment purchases, with multi-year allocations extending to FY2029.

• Administration prioritizes fentanyl and border crisis, supporting sustained funding for detection technologies.